Abortion Pills, FDA Approval, and Legal Battle: What’s at Stake in the Latest Reproductive Rights Fight

While litigation is pending challenging the regulatory clearance of abortion medications, the Biden administration has asked the Supreme Court to intervene to make them available. This move is in response to a recent judgement from the Fifth Circuit that maintained temporary restrictions on mifepristone pills.

U.S. Attorney General Merrick Garland was very unhappy with the appeals court’s ruling, which reversed a ruling from more than two decades earlier by a federal judge in Texas that had overturned the FDA’s approval of mifepristone, a medication used in more than half of all abortions in the United States. A judge in Texas has issued an injunction blocking the use of mifepristone, which goes into force on Friday.

Noting that the statute of limitations could be an impediment to the plaintiffs’ claim, the Fifth Circuit allowed the Biden administration’s emergency move to stay the Texas judgement until a complete appeal could be heard. A section of the Texas court’s ruling limiting access to mifepristone via postal prescription and requiring that only licensed physicians supply prescriptions was upheld by the appeals court.

Keep Reading

Experts say this judgement is one of the most important on reproductive rights since Roe v. Wade was handed down by the Supreme Court last year. The ruling is the result of a complaint filed in November by an anti-abortion group alleging that the FDA illegally allowed the use of mifepristone to terminate pregnancies, especially among teenage girls.

The Food and Drug Administration, along with other healthcare groups and the pharmaceutical industry, have voiced strong opposition to the Texas verdict, arguing that mifepristone is a safe and effective abortion medication. More than 400 pharmaceutical company CEOs signed an open letter expressing concern that the ruling could undermine government authority and affect the whole industry.

The FDA’s scientific judgment is at stake, and the Biden administration wants to ensure that all Americans have continued access to safe and effective reproductive care. Potentially far-reaching consequences for reproductive rights and healthcare access in the United States hinge on the outcome of the legal struggle over the regulatory licensing of mifepristone.

Noto

Jakarta-based Newswriter for The Asian Affairs. A budding newswriter that always keep track of the latest trends and news that are happening in my country Indonesia.

Recent Posts

V Surprises ARMY with Two Holiday Releases: A Festive Collab with Park Hyo-shin and “White Christmas” Cover

For K-pop fans, the Christmas season this year has become even more magical as several of their preferred stars reveal…

November 22, 2024

Celine Names TWS as Global Ambassadors Following Suzy Bae Announcement

After Suzy Bae's nomination as Celine's worldwide ambassador, the venerable French luxury fashion company has taken another bold step choosing…

November 22, 2024

Reddit Faces Widespread Outage, Users Turn to Workarounds Amid ‘Server Error’ Messages

Thousands of users of the well-known social network Reddit were left without access after a major outage of the website.…

November 22, 2024

Anne Hathaway Casted as ‘Verity’ in Colleen Hoover’s Book Adaptation

Anne Hathaway is slated to play the much expected film version of Colleen Hoover's best-selling book Verity in front of…

November 21, 2024

Gucci Set to Revolutionize Fashion Presentations with Unified Shows in 2025 under Sabato De Sarno’s Vision

Gucci is ready to change its presentation approach for 2025 in a radical action aimed to revolutionize the fashion industry.…

November 21, 2024

South Korea’s “Korea Discount”: Addressing the Governance Gap to Boost Market Value

As world investors wait for significant changes that might solve long-standing problems of governance and responsibility in South Korea's companies,…

November 21, 2024

This website uses cookies.

Read More